14α-Demethylase (CYP51) is a key enzyme in all sterol biosynthetic pathways (animals, fungi, plants, protists and some bacteria) catalyzing the removal of the C-14 methyl group following cyclization of squalene. Based on mutations found in CYP51 genes from Candida albicans azole-resistant isolates obtained after fluconazole treatment of fungal infections, and using site-direct mutagenesis, we have found that fluconazole binding and substrate metabolism vary among three different CYP51 isoforms, human, fungal and mycobacterial. In C. albicans, the Y132H mutant from isolates shows no effect on fluconazole binding whereas the F145L mutant results in 5-fold increase in its IC50 for fluconazole, suggesting that F145 (conserved only in fungal 14α-demethylases) interacts with this azole. In C. albicans, F145L accounts, in part, for the difference in fluconazole sensitivity reported between mammals and fungi providing a basis for treatment of fungal infections. While the C. albicans Y132H and human Y145H CYP51 mutants demonstrate essentially no effect on substrate metabolism, the Mycobacterium tuberculosis F89H CYP51 mutant loses both its substrate binding and metabolism. Since these three residues align in the three isoforms, the results indicate that their active sites contain important structural differences, and further emphasizes that fluconazole and substrate binding are uncoupled properties.
Introduction
Sterol 14α-demethylases (14DM) belong to a cytochrome P450 family (CYP51) catalyzing removal of a methyl group at position C14 in the sterol molecule (1) . This is a key step in cholesterol, ergosterol and phytosterol synthesis in animals, fungi and plants (2) . 14DM has also been found in mycobacteria and Methylococcus capsulatus where the reconstituted enzyme was found to convert sterols to their C14-demethylated products (3, 5) . Isoforms of 14DM from different kingdoms use very closely related sterol molecules as substrate and no other substrate molecules are known. Furthermore, mammalian and fungal forms show differences in their ability to bind azole molecules known to inhibit cytochrome P450 activities (6, 7) . For example, fungal 14DMs bind fluconazole several orders of magnitude more tightly than mammalian isoforms which was the basis for design of azole inhibitors targeting fungal 14DM versus the human form (8) . Inhibition of 14DM activity is lethal in fungi (9) , however treatment by fungistatic azole compounds leads to the emergence of resistant clinical isolates over time.
Several mechanisms involved in such resistance have been elucidated. Over-expression of efflux pumps results in decreased azole availability in the cells at the 14DM target site (10, 11) . A second way to counter deficiency in ergosterol availability is the ability of some isolates to use 14-methylated precursors such as 14-methylfecosterol for the sparking hormonal function observed with ergosterol (12) . In this case, accumulation of 14α-methyl-ergosta-8,24(28)-dien-3β,6α-diol, an ergosterol 14-methyl precursor, indicates that the azole resistance is caused by loss of sterol 14α-demethylase activity (12) . Finally, decreased affinity of 14DM for azole molecules is another cause of azole resistance. In this case, mutations in the CYP51 gene have by guest, on October 30, 2017 www.jlr.org Downloaded from 4 been identified in some azole-resistant strains (13, 15) . DUMC136, a Candida albicans (CA) drug resistant strain, is homozygous for multiple mutations in its CYP51 gene (16) and one of the most extensively studied azole-resistant isolates (16, 17) . When compared to an azole susceptible heterozygous strain ATCC 90028, it showed a 125-fold increase in its minimal fluconazole inhibitory concentration (MIC) for ergosterol biosynthesis in whole cells (16) . The CYP51 gene in the DUMC136 strain has two nucleotide substitutions compared to an allelic variant (ATCC 90028-2) of the fluconazole susceptible strain ATCC 90028, resulting in 2 amino acid changes: Y132H and F145L. When IC50 values were determined for CA 14DM in microsomal fractions, DUMC136 14DM showed only 10-fold increase in its resistance to fluconazole compared to the IC50 from ATCC 90028 or the wild type strain, without change in the 14α-demethylase activity (16) . When the single substitution Y132H was reproduced in CA 14DM and expressed in Saccharomyces cerevisiae, an increase in the IC50 value for fluconazole (12-fold compared to the wild type) was observed without any effect on the enzymatic activity (17) . This and subsequent studies clearly demonstrate that fluconazole binding and substrate metabolism are uncoupled events.
In order to better understand the molecular basis of fluconazole resistance and to begin explaining the differences seen in fluconazole inhibition between different 14α-demethylase isoforms (8), we used site-direct mutagenesis to reproduce substitutions Y132H and F145L in CA 14DM as found in the DUMC136 and other clinical isolates and compared their effect on fluconazole binding and substrate metabolism to their corresponding human and Mycobacterium tuberculosis (MT) 14DM orthologs. We found that the CA 14DM F145L mutant but not Y132H is responsible for the increase in fluconazole resistance, suggesting that in CA 14DM F145 interacts with the azole. While CA and human mutations did not notably affect catalytic activity, 
General methods
Flavodoxin, flavodoxin reductase and rat P450 reductase were kindly provided by Dr.
Chris Jenkins (18, 19 
Mutant construction
Primer sequences used for mutagenesis are represented in Table 1 
P450 expression and purification:
MT 14DM and its mutants are expressed and purified as described (3) 
Spectral analyses:
Sterol binding for MT 14DM and its mutants was performed as described (24) .
Fluconazole binding is carried out as described for sterol binding except that P450s are diluted to 5 µM in 1 ml of 20 mM MOPS, pH 7.5/50 mM KCl/5 mM MgCl 2 /10 % glycerol and titrated with 500 nM to 200 µM fluconazole for MT, human 14DMs, and their mutants and with 100 nM to 10 µM fluconazole for CA 14DM and its mutants. Spectra were recorded between 350 nm and 450 nm, revealing changes at 412 nm and 435 nm characteristic of a P450 Type II binding spectrum (6) . Since fluconazole is dissolved in ethanol, a corresponding volume of solvent was added simultaneously to the P450 chamber of the reference cuvette and the buffer chamber of the sample cuvette. The same results were obtained using DMSO. 
Results

Conservation of Y132 of C. albicans among CYP51s and its role in catalytic activity
A sequence alignment of 40 different 14α-demethylase isoforms shows that the CA 14DM Y132 residue is conserved among fungi and animals and corresponds to Y145 in human 14DM. In plant and bacterial isoforms, this position is occupied by phenylalanine and corresponds to F89 in MT 14DM (Fig. 2) . Y132, Y145 and F89 in CA, human and MT 14DMs, respectively, were substituted by histidine as found in CA clinical isolates. F145L also found in C. albicans clinical isolates, occasionally in combination with Y132H, was also reproduced only in the CA 14DM since this residue is not conserved in the human and MT isoforms. It is important to note that Y145 in human 14DM aligns with Y132 in CA and not F145 (Fig. 2) . In E. coli, 14DM mutants showed similar P450 expression levels to the corresponding wild types: MT 14DM and F89H mutant are expressed at 800 to 1200 nmole/L whereas H 14DM and its mutant are expressed at 200 nmole/L and CA 14DM and its mutants at 100 nmole/L.
Catalytic activities: 24,25-dihydrolanosterol (DHL) (Fig. 1 ) was used as substrate for both wild type and mutant forms. CA 14DM Y132H showed a 2-fold decrease in turnover number and F145L did not alter DHL metabolism. Human 14DM Y145H showed no change in turnover while, in MT the 14DM F89H mutant lost catalytic activity (Fig. 3) . This suggests that in CA and human 14DMs, Y132 and Y145 residues, respectively, are not required for activity, but in MT 14DM, F89 which aligns with these two, is required.
Role of CA 14DM mutants in fluconazole binding
Type II binding spectra: P450s were tested for their ability to bind fluconazole based on Type II binding spectra (6) . CA14DM Y132H mutant was found to have insignificantly higher by guest, on October 30, 2017 www.jlr.org Downloaded from affinity for fluconazole (2-fold decrease in Ks value) and F145L showed similar Ks value to the CA wild type (Fig. 4) . Neither H Y145H 14DM nor MT F89H mutants showed any change compared to the respective wild types (Fig. 4) Furthermore, the CA DUMC136 resistant strain (having both Y132H and F145L substitutions in its CYP51 gene) showed a 10-fold increase in its resistance to fluconazole (16) . In both latter studies, fluconazole affinity was determined based on IC50 and not Type II spectra as it is in our study. These results suggest that fluconazole interacts with different residues in CA and human isoforms and that this interaction depends on the P450 oxidation/reduction state and its environment (presence of the substrate, P450 reductase and DLPC). The difference in fluconazole binding seen between human and CA 14DMs (Fig. 5 ) and previously reported between mammalian and fungal isoforms (more than 5 orders of magnitude) (8) might be explained in part by presence of F145 in CA 14DM, absent in the human isoform.
Effect of F154L on
Role of F89 in MT 14DM/substrate binding: Loss of activity of the MT F89H mutant is due to a profound alteration in substrate binding (Fig. 6) . Indeed, DHL, lanosterol and 24M-DHL showed altered Type I binding spectra with a shift of the maxima from 390 nm to 412 nm (Fig. 6. A.). Estimated Ks values for F89H based on spectral changes are significantly higher (about an order of magnitude) for lanosterol and DHL and in the same order of magnitude for 24M-DHL (Fig. 6. B.) , suggesting a lower affinity for these substrates. The F89H mutant has lost any ability to bind obtusifoliol (Fig. 6 B. ) the best substrate for this enzyme (3, 24) and 24- (Fig. 1) , another C4-monomethyl sterol (not shown). Since CA Y132 is conserved among mammals and fungi, where this residue does not alter substrate metabolism, we also checked the substrate binding for the MT 14DM F89Y mutant. This mutant showed a moderate decrease (3-fold) in its catalytic activity (not shown) and slightly decreased affinity for DHL and lanosterol without effect on obtusifoliol binding (Fig. 6 B. ). However, when F89 is mutated to an alanine, the enzyme lost its catalytic activity and its ability to bind obtusifoliol as seen for F89H mutant (not shown). While obtusifoliol and 24-dihydroobtusifoliol are C4-monomethyl sterols, lanosterol, DHL and 24M-DHL are C4-dimethyl sterols (Fig. 1) . The fact that the F89H and F89A mutants do not bind obtusifoliol and F89H showed altered binding to DHL, lanosterol and 24M-DHL, suggests that the F89 residue in MT 14DM interacts with the sterol molecule at its C4β-methyl group. Interaction between F89H and C4-dimethyl sterols resulting in impaired Type I binding spectra without catalytic activity, suggests that another residue in the MT 14DM mutants interacts with the C4α-methyl group resulting in incorrectly positioned C4-dimethyl sterols. F89H and F89A lost their binding to obtusifoliol while F89Y did not, perhaps because an aromatic residue at the position 89 is required for obtusifoliol interaction at its C4β-methyl group.
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Discussion
These results imply that both azole and substrate binding are different in each of the three CYP51 isoforms studied. Since the structure of MT14DM is known, it is the easiest of the three to explain. MT14DM F89H did not show any effect in fluconazole binding based on Type II binding spectrum. Accordingly, crystal-structure determination of the MT 14DM fluconazolebound form showed no interaction between F89 and fluconazole (26) . In CA 14DM, Y132H mutant showed no effect on fluconazole binding but F145L substitution resulted in a 5-fold increase of IC50, a value similar to the one reported for the CA 14DM clone from the DUMC136 isolate (having both Y132H and F145L substitutions) when expressed in E. coli (27) . This suggests that F145L but not Y132H is responsible for fluconazole resistance. But when the same clone (having both mutations) is studied in microsomal fractions from CA, the IC50 increases by 10-fold (16), a value closer to the one reported for the single Y132H mutant expressed in Saccharomyces cerevisiae studied also in a microsomal fraction (12-fold) (17) . It is possible that the differences in fluconazole sensitivity of CA 14 DM mutants, seen between results using E. coli expression (data herein) (27) and fungal microsomal fractions (16, 17) may be due to differences in the lipid composition (DLPC in the reconstituted system and E coli membranes versus C. albicans and S. cerevisiae microsomes). Unexpectedly, the H14DM Y145H substitution resulted in a dramatic decrease in the IC50 value (3 orders of magnitude), suggesting a possible interaction of a histidine at this position with the fluconazole, leading to better positioning of the azole toward the heme center and therefore greater sensitivity for fluconazole of the human Y145H versus CA Y132H during the catalytic cycle. 
14
Another unexpected result was the loss of substrate metabolism and binding for MT14DM F89H and F89A mutants while corresponding mutants in CA and human had no effect on catalytic activity. This suggests that F89 in MT has a critical role in substrate/P450 interaction. Accordingly, systematic mutation in MT14DM of the conserved F83, G84 and D90 to alanine abolished catalytic activity (28) . Although residues F83, G84, D90 and F89 are part of SRS1 (substrate recognition site) defined for 14α-demethylases (29), crystal structure determination of substrate-free MT 14DM suggests that these residues are located in a B-C loop structure at the open surface of a putative access channel, about 20 Å from the heme iron, making interaction with the bound substrate unlikely without a profound conformational change (26) ( Fig. 7 A. ). But since the structure of the substrate-bound form of MT14DM has not yet been determined because of the highly nonpolar properties of the substrates, these results are difficult to explain. One possibility is that residues in the SRS1 and B-C loop region interact with the substrate during MT14DM/substrate recognition and contribute to its orientation at the heme center, an interaction that is lost once the substrate reaches the active site. Another possibility is that MT14DM/substrate binding induces a closing of the B-C loop allowing the substrate access to the active site. Thus the distance between F89 and the heme iron will become shorter and more comparable with the distances separating C4-and C14-methyl groups (Fig. 7. A. and C.) . Indeed, the B-C loop region has a high B factor value reflecting its high mobility (26) . In P450 BM3 (CYP102A1), another soluble P450 with known three dimensional structure, residue F87 also located in the B-C loop region showed different conformations in the absence or presence of the substrate (30) . P450 BM3 F87Y and F87G substitutions result in a decreased affinity and turnover numbers suggesting a critical role for the F87 in substrate binding and product release during the catalytic cycle (31) . Although MT 14DM and BM3 B-C loops are not superposed ( reflects structural differences in the active sites in the three CYP51 isoforms also observed in fluconazole binding studies. Even though these enzymes share great catalytic similarity, the proposed structural differences in their active sites are the basis for the design of drugs targeting selectively, microbial CYP51s versus the human isoform. It is interesting to note that fluconazole was designed to inhibit selectively CA CYP51 versus the human isoform in the absence of any structural data for these enzymes, suggesting differences between these isoforms. Based on mutations found in fluconazole resistant clinical-isolates, we have been able to show that these differences are the result of different interaction of selected residues in the three CYP51s studies with the inhibitor and the substrate indicating differences in their active site topologies. with mutated bases shown in parenthesis.
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